Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219's Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes

(marketscreener.com) Menin, a transcriptional scaffold protein, regulates pancreatic beta cell homeostasis; inhibiting menin function with BMF-219 increased beta cell function in a preclinical animal model, driving an improvement in glycemic control and insulin sensitivity.New data presented in a Short Oral Discussion, at EASD in Stockholm, Sweden, highlights the...https://www.marketscreener.com/quote/stock/BIOMEA-FUSION-INC-121456063/news/Biomea-Fusion-Presents-New-Preclinical-Data-at-the-European-Association-for-the-Study-of-Diabetes-E-41816493/?utm_medium=RSS&utm_content=20220920